15.96

1.40% 0.22

After Hours: 15.94 -0.02 -0.13%

Liquidia Corp (LQDA)

Overview News Price History Option Chain Financials Discussions Forecast

Liquidia Corp stock is traded at $15.96, with a volume of 881.86K. It is up +1.40% in the last 24 hours and up +31.03% over the past month. Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Previous Close:

$15.74

Open:

$15.81

24h Volume:

881.86K

Relative Volume:

1.06

Market Cap:

$1.35B

Revenue:

$17.49M

Net Income/Loss:

$-78.50M

P/E Ratio:

-13.30

EPS:

-1.2

Net Cash Flow:

$-52.85M

1W Performance:

+10.76%

1M Performance:

+31.03%

6M Performance:

+44.30%

1Y Performance:

+17.87%

1-Day Range:

$15.52

$16.18

1-Week Range:

$13.89

$16.18

52-Week Range:

$8.26

$16.99

Liquidia Corp Stock (LQDA) Company Profile

Name

Liquidia Corp

Sector

Healthcare (1177)

Industry

Biotechnology (679)

Phone

919.328.4400

Address

419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC

Employee

145

Twitter

@Liquidia_Inc

Next Earnings Date

2024-11-05

Latest SEC Filings

LQDA's Discussions on Twitter

Compare LQDA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LQDA Liquidia Corp	15.96	1.35B	17.49M	-78.50M	-52.85M	-1.20
VRTX Vertex Pharmaceuticals Inc	481.16	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	722.07	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	657.97	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	278.25	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	119.94	28.75B	3.30B	-501.07M	1.03B	-2.1146

Liquidia Corp Stock (LQDA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-24	Initiated	Wells Fargo	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-19-24	Upgrade	Raymond James	Outperform → Strong Buy
Aug-16-24	Initiated	Raymond James	Outperform
Jun-25-24	Initiated	Oppenheimer	Perform
Jan-05-24	Reiterated	Needham	Buy
Sep-19-22	Resumed	Wedbush	Underperform
Sep-01-22	Downgrade	Wedbush	Neutral → Underperform
Jul-22-22	Initiated	Ladenburg Thalmann	Buy
May-31-22	Initiated	BTIG Research	Buy
May-26-22	Initiated	BofA Securities	Buy
Dec-04-20	Initiated	H.C. Wainwright	Buy
Nov-20-20	Downgrade	Wedbush	Outperform → Neutral
Nov-08-18	Resumed	Jefferies	Buy
Sep-05-18	Initiated	Wedbush	Outperform
Aug-20-18	Initiated	Jefferies	Buy
Aug-20-18	Initiated	Needham	Buy

View All

Liquidia Corp Stock (LQDA) Latest News

Feb 06, 2025

Stock Performance Spotlight: Liquidia Corp (LQDA) Ends the Day at 15.74, Up by 3.89 - The Dwinnex

Feb 06, 2025

Liquidia Corp.: We Have Exposure To The Upside Now - Seeking Alpha

Feb 06, 2025